Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2021)

RedHill Biopharma has reported Non-Current Debt over the past 2 years, most recently at $83.6 million for Q4 2021.

  • Quarterly Non-Current Debt rose 2.74% to $83.6 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $83.6 million through Dec 2021, up 2.74% year-over-year, with the annual reading at $83.6 million for FY2021, 2.74% up from the prior year.
  • Non-Current Debt was $83.6 million for Q4 2021 at RedHill Biopharma, up from $81.4 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $83.6 million in Q4 2021 and troughed at $81.4 million in Q4 2020.